Navigation Links
Talyst Receives Multiple Honors for Workplace Excellence
Date:7/9/2009
Company Recognized for Exceptional Benefits, Work and Life Equilibrium and Leadership Culture
Bellevue, WA (PRWEB) July 9, 2009 -- Talyst, a leader in pharmacy automation systems, found June to be an award-filled month as it received kudos for cultivating an excellent work environment. Talyst was awarded as one of "Washington's 100 Best Companies to Work For 2009" by Seattle Business Monthly, and is a finalist for the Puget Sound Business Journal's "Washington's Best Workplaces."
Talyst is a relatively small company with just over 100 employees, but its products play a crucial role in health care facilities. Talyst provides automated medication management hardware and software to acute care hospital pharmacies, long-term care facilities and correctional facilities nationwide. With Talyst's products, the right medications go to the right patient at the right time and in the right dose. It is fast-paced and demanding work, but Talyst's employees meet that challenge.
"Our employees are the lifeblood of our company, and we work hard to provide them with a productive, positive and fun work environment," said Carla Corkern, Talyst CEO and chairman of the board. "Most rewarding for all of us, however, is knowing the profound impact our work has on both improving safety outcomes for patients in health care facilities and diminishing the waste footprints generated by traditional medication dispensing methods."
Talyst has been recognized by both awards for providing excellent benefits, work/life balance and an exceptional leadership culture. Talyst earned these honors by offering flexible schedules to ensure that employees' family is never neglected; scheduling quarterly All-Hands Meetings to deliver honest fiscal outlooks, share smart
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |
Related medicine news :
1. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
2. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
3. Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device
4. Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results
5. Americas #1 Companion Gets Respect: The CATalyst 2009 Top 10 Cat-Friendly Cities
6. Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction
7. The Catalyst Foundations Groundbreaking ACE Study-Based Services Bring Transformational Change to Healthcare
8. Upcoming Packard/Stanford Autism Symposium a Catalyst for Collaboration among Researchers and Community
9. Talyst Moves Patient Safety and Inventory Control Beyond the Hospital
10. Talyst Unveils InSite for Long-Term Care
11. Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
Post Your Comments:
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has announced an ... a new Medicare Advantage Plan for PREFERRED’s provider network ... Arizona counties. The agreement takes effect in two stages: ... and Maricopa and Pima counties will become effective on ... of WellCare of Arizona has Medicare Advantage plans in ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... don’t go to bed or rise early thanks to a ... , Crafty travelers will have a little extra change ... Scottsdale Paradise Valley hotel’s Book Early and Save Up ... advance notice, guests can enjoy the year-round Scottsdale sunshine in ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4[0] States vary widely on success rates for minorities in drug treatment programs[0] Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds[0] GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health[0] PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network[0] Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley
... researchers at Peterson Medical College, a strategy was developed ... Immunodeficiency Virus (HIV) out of dormancy in the cellular ... Samoan rainforest tree, and appears to stimulate the virus, ... body's immune system to detect and attack it.// ...
... heart attacks more quickly and with greater accuracy if ... ,At the moment, the blood test is usually the ... used earlier on, the researchers argue, it would also ... Baltimore University in Maryland, led the research.// His team ...
... A breakthrough in the treatment of coronary artery disease ... surgery. Medical research has come up with a drug-coated ... has shown an ability to check the recurrence of ... ,The results of this new procedure, based on a ...
... of what causes the fatal autoimmune disease Systemic Lupus ... possible genetic link. ,Researchers at the University of ... possible genetic link to SLE. Their report in a ... in mice which, if absent, causes symptoms remarkably similar ...
... to detect cervical cancer,has been developed by Australians which may ... the UK, Italy, Spain as well as Australia. ,Sydney-based ... with CSIRO and claims that it offers instant results and ... pen-like probe to collect information directly from the cervix about ...
... Scientists working on the 10-year international Human Genome Project ... the highest concentration of disease genes.Out of 23 pairs ... with genetic disease. , Over the next 20 years ... Cambridge, eastern England will have a large impact on ...
Cached Medicine News:Health News:Prostratin- Drug to eradicate HIV 2Health News:Blood test for diagnosis of heart attacks 2Health News:Bypassing open heart bypass surgery... 2Health News:Identification of gene 2(Date:6/19/2013)... June 19, 2013 Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4). Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6[0] Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer[0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence[0] NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
... FARMINGDALE, N.Y., Feb. 9, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative, therapeutic, ... neurosurgery, laparoscopic surgery, and other surgical and medical ... fiscal quarter and six months ending December 31, ...
... SAN FRANCISCO, Feb. 9, 2011 SYNARC, ... to the pharmaceutical and biotechnology industries, announced today that ... and marketing efforts in support of the company,s rapidly ... Ciaran Cooper, a pioneer in the clinical trials ...
Cached Medicine Technology:Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6SYNARC Appoints Ciaran Cooper as Vice President, Business Development 2Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |